Results 1 to 10 of about 871 (113)

Antimony susceptible Leishmania donovani: evidence from in vitro drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era [PDF]

open access: yesMicrobiology Spectrum
Post-kala-azar dermal leishmaniasis (PKDL) patients are a key source of Leishmania donovani parasites, hindering the goal of eliminating visceral leishmaniasis (VL). Monitoring treatment response and parasite susceptibility is essential due to increasing
Sushmita Ghosh   +6 more
doaj   +2 more sources

RETRACTED: Leishmania donovani isolates with antimony-resistant but not -sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation.

open access: yesPLoS Pathogens, 2010
The inability of sodium antimony gluconate (SAG)-unresponsive kala-azar patients to clear Leishmania donovani (LD) infection despite SAG therapy is partly due to an ill-defined immune-dysfunction.
Arun Kumar Haldar   +8 more
doaj   +4 more sources

Bronchoalveolar Lavage Fluid Metagenomic Second-Generation Sequencing Assists in Guiding the Treatment of Visceral Leishmaniasis: A Case Report [PDF]

open access: yesInfection and Drug Resistance
Jian Li,1,* Li Liu,2,* Zhiyun Gao,1 Xia Chuai,3 Xiaokun Liu,4 Xiaobo Zhang,2 Xinyu Zhang,2 Xiaoqing Su,2 Qian Xu,2 Zhuojun Deng2 1Department of Pathogenic Biology, Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China ...
Li J   +9 more
doaj   +2 more sources

Leishmaniasis with secondary hemophagocytic syndrome: a case report [PDF]

open access: yesZhenduanxue lilun yu shijian, 2022
Leishmaniasis is an infection caused by Leishmania. Different species of Leishmania cause different clinical syndromes. Hemophagocytic syndrome (HPS) is an immune related systemic inflammatory response syndrome mediated by many factors.
XIONG Xinhai, LI Jia, DING Xiaosong, JI Congcong, SHI Hourong, XIANG Minjie
doaj   +1 more source

Treatment of leishmaniasis with chemotherapy and vaccine: a mathematical model

open access: yesJournal of Biological Dynamics, 2023
Leishmaniasis, an infectious disease, manifests itself mostly in two forms, cutaneous leishmaniasis (CL) and, a more severe and potentially deadly form, visceral leishmaniasis (VL).
Nourridine Siewe, Avner Friedman
doaj   +1 more source

Therapeutic modalities in post kala-azar dermal leishmaniasis: A systematic review of the effectiveness and safety of the treatment options

open access: yesIndian Journal of Dermatology, 2021
Post-kala-azar dermal Leishmaniasis (PKDL) is one of the important neglected tropical diseases, which has a tremendous epidemiological significance, being the reservoir of kala-azar.
Adrija Datta   +4 more
doaj   +1 more source

Antimony resistant Leishmania donovani but not sensitive ones drives greater frequency of potent T-regulatory cells upon interaction with human PBMCs: role of IL-10 and TGF-β in early immune response. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2014
In India the sand fly, Phlebotomus argentipes, transmitted parasitic disease termed kala-azar is caused by Leishmania donovani (LD) in humans. These immune-evading parasites have increasingly developed resistance to the drug sodium antimony gluconate in ...
Rajan Guha   +5 more
doaj   +1 more source

Runx proteins mediate protective immunity against Leishmania donovani infection by promoting CD40 expression on dendritic cells.

open access: yesPLoS Pathogens, 2020
The level of CD40 expression on dendritic cells (DCs) plays a decisive role in disease protection during Leishmania donovani (LD) infection. However, current understanding of the molecular regulation of CD40 expression remains elusive.
Md Naushad Akhtar   +8 more
doaj   +1 more source

Cutaneous leishmaniasis

open access: yesJournal of Pathology of Nepal, 2017
Leishmaniasis is considered to be zoonotic disease, caused by a protozoan parasite of the genus Leishmania, and transmitted by a bite of infected female sandfly.
Ram Chandra Adhikari, Mahesh Shah
doaj   +1 more source

Home - About - Disclaimer - Privacy